Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial

Daniel B Rosen, Cory D Benjamin, Joanna C Yang, Connor Doyle, Zhigang Zhang, Chris A Barker, Max Vaynrub, T Jonathan Yang, Erin F Gillespie, Daniel B Rosen, Cory D Benjamin, Joanna C Yang, Connor Doyle, Zhigang Zhang, Chris A Barker, Max Vaynrub, T Jonathan Yang, Erin F Gillespie

Abstract

Background: In patients with metastatic cancer, the bone is the third-most common site of involvement. Radiation to painful bone metastases results in high rates of pain control and is an integral part of bone metastases management. Up to one-third of inpatient consults are requested for painful bone metastases, and up to 60% of these patients had evidence of these lesions visible on prior imaging. Meanwhile recent advances have reduced potential side effects of radiation. Therefore, there is an opportunity to further improve outcomes for patients using prophylactic palliative radiation to manage asymptomatic bone metastases.

Methods/study design: In this trial, 74 patients with metastatic solid tumors and high-risk asymptomatic or minimally symptomatic bone metastases will be enrolled and randomized to early palliative radiation or standard of care. This will be the first trial to assess the efficacy of prophylactic palliative radiation in preventing skeletal related events (SREs), the primary endpoint. This endpoint was selected to encompass patient-centered outcomes that impact quality of life including pathologic fracture, spinal cord compression, and intervention with surgery or radiation. Secondary endpoints include hospitalizations, Bone Pain Index, pain-free survival, pain-related quality of life, and side effects of radiation therapy.

Discussion: In this study, we propose a novel definition of high-risk bone metastases most likely to benefit from preventive radiation and use validated questionnaires to assess pain and impact on quality of life and health resource utilization. Observations from early patient enrollment have demonstrated robustness of the primary endpoint and need for minor modifications to Bone Pain Index and data collection for opioid use and hospitalizations. With increasing indications for radiation in the oligometastatic setting, this trial aims to improve patient-centered outcomes in the polymetastatic setting.

Trial registration: ISRCTN Number/Clinical trials.gov, ID: NCT03523351 . Registered on 14 May 2018.

Keywords: Bone metastasis; Patient-centered outcomes; Radiation therapy; Skeletal-related events (SRE).

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study Schema

References

    1. Gomez DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. doi: 10.1016/S1470-2045(16)30532-0.
    1. Nguyen QN, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5(6):872–878. doi: 10.1001/jamaoncol.2019.0192.
    1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–593. doi: 10.1038/nrc867.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23(2):129–138.
    1. Steenland E, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study. Radiother Oncol. 1999;52(2):101–109. doi: 10.1016/S0167-8140(99)00110-3.
    1. Sze WM, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004;2:CD004721.
    1. Zimmermann C, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014;383(9930):1721–1730. doi: 10.1016/S0140-6736(13)62416-2.
    1. Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742. doi: 10.1056/NEJMoa1000678.
    1. Hartsell WF, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798–804. doi: 10.1093/jnci/dji139.
    1. van der Linden YM, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004;59(2):528–537. doi: 10.1016/j.ijrobp.2003.10.006.
    1. Chow E, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–1436. doi: 10.1200/JCO.2006.09.5281.
    1. Rich SE, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126(3):547–557. doi: 10.1016/j.radonc.2018.01.003.
    1. Yang, J.C., et al., Radiation for bone metastases: Reconsidering the optimal timing. Journal of Clinical Oncology, 2017. no. 15_suppl: p. 10122–10122.
    1. Lipton A, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082–1090. doi: 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>;2-Z.
    1. Saad F, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–882. doi: 10.1093/jnci/djh141.
    1. Rosen LS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–2621. doi: 10.1002/cncr.20308.
    1. Shulman RM, et al. External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs) Ann Palliat Med. 2019;8(2):159–167. doi: 10.21037/apm.2018.10.04.
    1. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;249:256–264.
    1. Faruqi S, et al. Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery. 2018;83(3):314–322. doi: 10.1093/neuros/nyx493.
    1. Duran I, Fink MG, Bahl A, Hoefeler H, Mahmood A, Lüftner D, Ghazal H, Wei R, Chung KC, Hechmati G, Green J, Atchison C. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. Eur J Cancer Care (Engl). 2017;26(6). 10.1111/ecc.12452. Epub 2016 Feb 10. PMID: 26865392.
    1. Luftner D, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus. 2014;3:328. doi: 10.1186/2193-1801-3-328.
    1. Stopeck A, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012;15(4):712–723. doi: 10.3111/13696998.2012.675380.
    1. Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2010;67(1):4–11. doi: 10.1016/j.lungcan.2009.08.020.
    1. Cox BW, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83(5):e597–e605. doi: 10.1016/j.ijrobp.2012.03.009.
    1. Bilsky MH, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324–328. doi: 10.3171/2010.3.SPINE09459.
    1. Khan I, et al. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14:60. doi: 10.1186/s12955-016-0455-1.
    1. Pickard AS, et al. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007;45(3):259–263. doi: 10.1097/01.mlr.0000254515.63841.81.
    1. Boehling NS, et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine. 2012;16(4):379–386. doi: 10.3171/2011.11.SPINE116.
    1. Himelstein AL, et al. Effect of longer-interval vs standard dosing of Zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48–58. doi: 10.1001/jama.2016.19425.
    1. Palma DA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. doi: 10.1186/s12885-019-5977-6.
    1. Gomez DR, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with Oligometastatic non-small-cell lung Cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565. doi: 10.1200/JCO.19.00201.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner